@EllipsesPharma

Global leader in developing innovative cancer treatments. We're accelerating progress for a world where cancer is history.

[@EllipsesPharma @ellipsespharma]

Dr. Krebs underscores the role of targeting resistance mechanisms & CNS activity the treatment of RET+ NSCLC. EP0031 emerges as a promising solution. Watch our full discussion https://t.co/XkG4t01p8z #CancerResearch #Innovation

[@EllipsesPharma @ellipsespharma]

Introducing Professor @EmilianoCalvo_, Director of Clinical Research at START Madrid and a pivotal member of our Scientific Affairs Group (SAG) at Ellipses Pharma. His leadership in early-phase clinical drug development is driving innovation in oncology. #ClinicalResearch

[@EllipsesPharma @ellipsespharma]

Meet Professor Patrick Schöffski (@schoffski), a key member of our Scientific Affairs Group (SAG) at Ellipses Pharma. With expertise in medical oncology and experimental oncology research, he brings invaluable insights to advancing cancer treatments. #Oncology #PrecisionMedicine

[@EllipsesPharma @ellipsespharma]

Prof. Giuseppe Curigliano is an esteemed member of our Scientific Affairs Group at @ellipsespharma. With expertise in oncology research and a commitment to advancing cancer treatment, he exemplifies our dedication to innovation. Learn more about our SAG: https://t.co/5k57mBu4FB

[@EllipsesPharma @ellipsespharma]

Our team will be at #ASCO24 from May 31 to June 4. Join us as Dr Elena Garralda presents phase one study data for EP0031/A400. Developed with Kelun-Biotech EP0031 has entered phase-2 clinical development cleared by the FDA. Don't miss Dr Garralda's presentation at 1:30 on June 3

[@EllipsesPharma @ellipsespharma]

Dr. Elena Garralda Cabanas of VHIO explores the promising data behind EP0031 demonstrating efficacy and safety in trials for patients with advanced RET-altered tumors. Now granted FDA orphan drug status. Watch full interview: https://t.co/6Y32MpadAy #MedicalInnovation

[@EllipsesPharma @ellipsespharma]

On World Clinical Trials Day we acknowledge the crucial role of clinical trials in transforming treatment approaches. Ellipses Pharma is dedicated to swiftly advancing innovative cancer medicines through rigorous trials to reach patients who need them the most. #ClinicalTrialsDay

[@EllipsesPharma @ellipsespharma]

Reflecting on impactful discussions at Abu Dhabi Global Healthcare Week @ADGHWTweets. As Knowledge & Oncology Partner, @ellipsespharma is committed to driving innovation and improving patient outcomes. #ADGHW #HealthcareCollaboration #EllipsesPharma

[@EllipsesPharma @ellipsespharma]

Right now, Professor Sir Christopher Evans, Chairman of @ellipsespharma, delivers a keynote at Abu Dhabi Global Healthcare Week @ADGHWTweets His insights cover precision medicine, AI, and more, shaping the future of healthcare. Stay tuned for updates! #HealthcareInnovation

[@EllipsesPharma @ellipsespharma]

Today, Abu Dhabi Global Healthcare Week @ADGHWTweets kicks off! As Knowledge & Oncology Partner, Ellipses Pharma supports this event. Join us in exploring innovative solutions and driving change in healthcare. #ADGHW #HealthcareInnovation #EllipsesPharma

[@EllipsesPharma @ellipsespharma]

On Monday, Abu Dhabi Global Healthcare Week @ADGHWTweets begins! Don't miss Prof. Sir Chris Evans, Chairman of Ellipses Pharma, sharing insights on the future of global healthcare. Stay tuned for updates! #ADGHW #Healthcare #SirChrisEvans

[@EllipsesPharma @ellipsespharma]

Today is Ovarian Cancer Awareness Day. Like many cancers, swift and effective care is crucial as this disease can go undetected until later stages. Today we stand with all those affected as we continue in our mission to drive drug development forward. #OvarianCancerAwareness

[@EllipsesPharma @ellipsespharma]

Exciting news: FDA clears our next-gen selective RET inhibitor, EP0031/A400, for Phase 2 clinical development. Promising results in NSCLC, thyroid, and other solid tumors. Stay tuned for @ASCO2024 presentation on June 3rd https://t.co/BPP1YL4hyu
#ClinicalTrials #CancerResearch

[@EllipsesPharma @ellipsespharma]

Dr. Matthew Krebs discusses the transformative potential of EP0031 in RET-altered cancer care. Preliminary data from 109 patients reveal promising efficacy and safety outcomes. Dive deeper into the conversation on our website https://t.co/XkG4t01WY7 #EP0031

[@EllipsesPharma @ellipsespharma]

Discover how Ellipses Pharma is transforming drug development in oncology to benefit patients sooner. Our CEO @ellipses_CEO shares insights on our streamlined approach. Read more: https://t.co/cKEgDe5HEA #Oncology #Innovations #HealthAwareness2024

[@EllipsesPharma @ellipsespharma]

Excited to join forces with @guardian and @mediaplanet in the Innovations in Oncology series! Discover how Ellipses Pharma is pioneering next-gen therapies for leukaemia, breast, and lung cancer. https://t.co/JcZZabsInV #InnovationsInOncology #EllipsesPharma #HealthAwareness2024

[@EllipsesPharma @ellipsespharma]

Chief Medical Officer @ellipsesCMO discusses how EP0031 revolutionises cancer treatment in @Daily_Express Read the article here: https://t.co/RPU71Sazdh
#EP0031 #CancerResearch #PrecisionMedicine #Innovation

[@EllipsesPharma @ellipsespharma]

Explore the cutting-edge of lung cancer treatment with @EllipsesCMO. Learn about the latest breakthroughs in clinical trials and the growing demand for next-generation therapies. Read more: https://t.co/cBsrpx5Cj5 #LungCancer #PrecisionMedicine #Innovation #EllipsesPharma

[@EllipsesPharma @ellipsespharma]

AS SEEN ON TV: Learn about our role in advancing Precision Medicine and how we validate promising assets through our Scientific Advisory Group. Check out the interview: https://t.co/lTRAaR0lth #PrecisionMedicine #EllipsesPharma

[@EllipsesPharma @ellipsespharma]

EP0031/A400 granted Fast Track designation by FDA for RET-fusion NSCLC. Accelerating
hope for patients! Read the full release: https://t.co/rd0mth97mS #FastTrack #EllipsesPharma